



INTELLECTUAL
PROPERTY OFFICE
BRUNEI DARUSSALAM

31 January 2023

NO. 001/2023



PATENT JOURNAL

Brunei Darussalam Intellectual Property Office (BrulPO)

The Law Building, Ground Floor

Jalan Raja Isteri Pengiran Anak Saleha

Bandar Seri Begawan BA1910

Negara Brunei Darussalam

Tel: +673 2244873/4/5/6 Ext 102

Email: enquiries@bruipo.gov.bn

Brunei Darussalam Intellectual Property Office (BrulPO) © 2013. All rights reserved. Modification or reproduction of this Journal without the permission of BrulPO is prohibited.





CONTENTS

General Information	3
Operating Hours	3
Submission of Application	3
Enquiries	3
Patents Legislation	4
Forms and Fees	4
INID Codes	5
First Schedule – Fees	7
Second Schedule – Forms	15
Third Schedule – Scale of Cost Part 1 – Basic Costs	19
Part II – Additional Cost	20
Fourth Schedule – Micro-Organisms	21
Fifth Schedule – Remuneration of Scientific Advisers	27
New Patent Applications Filed	34
Patent Renewal Application	59
Patent Granted	75



General Information

The Brunei Darussalam Intellectual Property Office (BruIPO) is an Office under the Attorney General's Chamber and its premises with effect from the 1 April, 2019 and is situated at the following address:

Brunei Darussalam Intellectual Property Office (BruIPO)
Attorney General's Chamber
The Law Building,
Jalan Raja Isteri Pengiran Anak Hajah Saleha,
Bandar Seri Begawan BA1910
Brunei Darussalam
Tel: +673 2225919

Opening Hours

With effect from 1 January, 2020, the Brunei Intellectual Property Office (BruIPO) counter will operate as follows:

Monday to Thursday	: 8.00am to 12.00pm 2.00pm to 3.00pm
Saturday	: 8.00am to 11.00am
Friday and Sunday	: CLOSED

Submission of Applications

1. All applications for the registration of patents must be lodged with the Registrar of Patents at the Brunei Darussalam Intellectual Property Office (BruIPO).
2. Submission of applications via fax is acceptable provided the documents transmitted are clear and legible (in particular, representations). For applications that require the payment of a fee, actual lodgement of the prescribed fee is required before such applications can be processed.

Enquiries

1. For enquiries relating to any information in this Journal, kindly contact the Office at telephone numbers +673 2225919. Hard copies of the Journal can be purchased upon request from the Office at a cost of B\$10.00 per copy.
2. The website of the Brunei Darussalam Intellectual Property Office (BruIPO) is <http://www.bruipo.gov.bn>.
3. All Patent-related enquiries via email can be submitted to enquiries@bruipo.gov.bn



Patents Legislation

1. The legislation governing the registration of Patent in Brunei Darussalam is the Patents Order 2011, while the subsidiary legislation is the Patents Rule, 2012.
2. The hard copies of the legislation can be purchased from: Print Plus Sdn Bhd Prime Minister's Office Jalan Airport Lama Bandar Seri Begawan BB3510 Brunei Darussalam Tel: 238 2541
3. The soft copies of the legislation can be obtained from www.bruipo.gov.bn

Forms and Fees

1. For any proceedings before the Registry, the prescribed form to be used and the accompanying fee payable shall be in accordance with the First and Second Schedule of the Patents Rule, 2012.
2. Payment by cheque should be made out to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

Restrictions on Applications Abroad by Residents of Brunei Darussalam

1. Local applicants intending to file a patent abroad must first obtain the Registrar's written authority as prescribed under section 33(1) of the Patents Order, 2011.
2. Failure to observe this requirement is an offence under section 33(1)(b)(3) of the Order.

Transitional Applications

1. Transitional applications under Section 115 shall be lodged with the Registrar of Patents in the following manner:
 - Request to the Registrar of Patents for re-registration of a Singapore, Malaysia or United Kingdom/European patent;
 - Lodgement of Patent Form PF46;
 - Certified true copy of the grant of patent in the relevant country;
 - Prescribed fee of B\$250.00; and
 - Any other supporting documents that the Registrar deems necessary.
2. The filing of a Power of Attorney accompanying a request for re-registration is no longer a requirement with effect from 1 January 2012.



3. Any renewal due for patents registered under the repealed Inventions Act (Cap 72) on or after 1 January 2012 shall be made in accordance with Section 54 on Patents Form PF20. Applicants must furnish supporting documents proving the validity of the patents which are due for renewal.

4. Search on the Register of patents (re-registrations) can be conducted at the Office by completing a Search Form PF30 and the payment of a search fee of \$6.50 per hour.



'INID' NUMBERS IN USE ON BRUNEI PATENT DOCUMENTS

'INID' is an acronym for Internationally agreed Numbers for the Identification of Data'

(10) Document identification

- (11) Number of the document
- (12) Plain language designation of the kind of document
- (19) WIPO country code, or other identification, of the country publishing the document.

(20) Document filing data

- (21) Number(s) assigned to the application(s)
- (22) Date(s) of filing application(s)
- (23) Other date(s) of filing, including exhibition filing date and date of filing complete specification following provisional specification.
- (24) Date from which industrial property rights may have effect.

(30) Priority data

- (31) Number(s) assigned to priority application(s).
- (32) Date(s) of filing priority application(s).
- (33) Country (countries) in which the priority application(s) was (were) filed.

(40) Date(s) of making available to the public

- (43) Date of publication by printing or similar process of unexamined document, on which no grant has taken place on or before the said date.
- (44) Date of publication by printing or similar process of an examined document, on which no grant has taken place on or before the said date.
- (45) Date of publication by printing or similar process of a document, on which grant has taken place on or before the said date.
- (47) Date of making a granted patent available to the public by viewing, or copying on request

(50) Technical information

- (51) International Patent Classification
- (52) Domestic or national classification
- (54) Title of invention
- (56) List of prior art documents, if separate from descriptive text.
- (57) Abstract or claim.

(60) Reference(s) to other legally related domestic document(s)

- (60) Related by cognate(s).
- (61) Related by addition(s).
- (62) Related by division(s).

(70) Identification of parties concerned with the document



- (70) Name(s) of nominated person
- (71) Name(s) of applicant(s).
- (72) Name(s) of inventor(s) if known to be such.
- (74) Name(s) of attorney(s) or agent(s).
- (75) Name(s) of inventor(s) who is (are) also applicant(s)

(80) Identification of data related to International Conventions other than the Paris Convention

- (86) PCT Application Number.
- (87) PCT Publication Number.

NOTE

- (1) The classification used is the International Patent Classification and is identified by the INID code (51). Further editions of the classification are identified as (51)2, (51)3, (51)4 and (51)5.
- (2) INID code 74 provides for the name of patent attorney, or firm of attorneys, prosecuting an application.



PRACTICE NOTE 2012/01

PATENT RENEWALS

• RENEWAL OF PATENTS REGISTERED UNDER SECTION 115 OF THE PATENTS ORDER

1. For Section 115 applications, the following original documents need to be signed and submitted to the Registry of Patents:

- (a) PF20;
- (b) PF46 (for the first instance of renewal payment if that agent is not previously appointed);
- (c) evidence of the original patent not having been revoked, and
- (d) a cheque drawn on a Brunei bank account including the correct fee for both the PF20 and PF46. Cheques must be made payable to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

2. PF20

The notes at the top of the form and applicable provisions in the Patents Order and Patent Rules should be followed strictly. Additional formatting guidelines are as follows:

Section 2: Brunei registration number in format RP/XX/YYYY for pre 2012 cases, and RE YYYY/XXXX for 2012 onwards.

Section 3: Original Patent number in the format UK: GBXXXXXXX or EPXXXXXXX; MY: MY-XXXXXX-A; and SG: XXXXX.

Section 4: This should match the current details on the Brunei Register (rather than the original patent register details).

Section 5: Agents attending to the renewal on behalf of the proprietor should leave Section 5 blank and instead fill in details in Section 7 and 8.

Section 6: The renewal deadline is calculated from the date of filing for all UK, MY and SG original cases.

3. PF46

Section 6: Most commonly the appointment is for renewal matters only, so the "for renewals only" box should be checked, assuming the agent has not been previously appointed.

4. PF21

Extension fees will become payable for renewals as of 1 January 2013.

5. Certification of original patent

Evidence must be provided that the original patent must not be "revoked" as of the date of the renewal being paid. Please note it does not matter if the original patent has "lapsed" or "ceased". Evidence can be in the form of a certified true copy of the applicable online register printed on the day of filing or a



statutory declaration to the same effect. The online register of the original patent can be printed and certified as a true copy by the authorised agent for the renewal using a suitable chop and signature.

- **EXPIRY OF PATENT AT THE END OF THE TERM OF THE PATENT**

6. Agents are reminded that under Section 115(4)(a), the term of a Section 115 patent is 20 years from the date of filing of the original (UK/MY/SG) patent; subject to Section 35 and 36. It does not make any difference which country the original patent is from.

AMENDMENT OF RULE 92 OF S 19/2012

Rule 92 of the Patent Rules, 2012, is amended by repealing sub-rule (1) and by substituting the following new sub-rule therefor –

“(1) Subject to this rule, in relation to an international application for a patent (Brunei Darussalam) which is, under section 82, to be treated as an application for a patent under the Order, the prescribed period for the purpose of section 83(3) and (5) shall be, in a case where Brunei Darussalam has been designated and/or elected in accordance with the Patent Co-operation Treaty, 30 months from the relevant date.”.

AMENDMENTS AND CORRECTIONS

- **AMENDMENT OF SPECIFICATION (RULES 51) OR CORRECTION OF ERROR IN SPECIFICATION (RULE 64)**


1. Unless required by the Registry under rules 51, an application for amendment of specification or a request for correction of an error in proposed amendment/correction incorporated; only a copy of the specification with the amendment/ correction indicated clearly therein is required. If a copy of the specification with the proposed amendment/correction incorporated is nonetheless filed, please be informed that the Registry will not review that document or consider it in any proceedings before the Registry.
2. The registry would also like to point out the replacement sheets with clear markings will reduce the need for clarification or further correspondences and hence will help expedite the processing of such requests.

- **AMENDMENTS/CORRECTIONS TO SPECIFICATION AND ABSTRACT**


1. Amendments/corrections to patent specifications and abstracts are to be clearly marked and completed by striking through text/figure etc. to be replaced, and by underlining replacement text/figure etc.
2. The following 3 examples reflect 3 possible alternative ways to which the changes could be represented. Example 4 reflects a situation where Patents Form 19 is filed.



Example 1: Page 10 of 19 sheets (Specification) is amended




Example 2: Page 10 of 19 sheets (Specification) is amended






Example 3: Page 10 of 19 sheets (Specification) is amended



This vertical line indicates the matter replacing the whole of page 10. To facilitate the document reproduction process however, the line should be placed about 0.5 cm to 1cm away from the 2.5 cm margin of each sheet.

Example 4: Page 10 of 19 sheets (Specification) is amended





• **COMMONLY MADE MISTAKES WHEN FILING PATENTS FORM 17**

The following are some of the commonly made mistakes in relation to making a request for amendments –

- Replacement sheets for amendments are not filed with Patents Form 17. –
- There is no marked up copy enclosed with Patents Form 17. –
- Patents Form 17 is filed without any replacement sheet. -
- Amendments to be made given on Patents Form 17 are different from the replacement sheets.

REGISTRATION UNDER SECTION 115

The following applications were processed through the Registry of Patents under section 115 of the Patents Order, 2011. Application numbers beginning with 'RP' are applications which were filed under the repealed Inventions Act (Cap 72) and were pending on 1 January 2012. Application numbers beginning with 'RE' are new re-registration applications filed after the implementation of the new Patents Order, 2011.

Date of filing:	17 February, 2020
Application No.:	RE/R/2020/0001
Patent No.:	EP2580236 B1 and US352461 P
Date of Grant:	8 June, 2011
Applicant (s)/Proprietor(s):	ASTRAZENECA AB and PIERIS PHARMACEUTICALS GMBH
Title:	TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA



FIRST SCHEDULE

FEES PAYABLE

<u>Matter</u>	<u>Fee</u>	<u>Corresponding Form(s)</u>
1. On filing a request for the grant of a patent	\$160.00	1
2. On reference under section 20(1) or 48(1)	\$450.00	2
3. On filing a counter-statement in each of the following cases –	\$40.00	3
(a) Opposing the making of an order under section 20 or 48		
(b) Opposing a request under section 22		
(c) In respect of a reference under section 23(5)		
(d) Opposing an application under section 24		
(e) In answer to a notice of opposition under section 38		
(f) In answer to a notice of opposition under section 41		
(g) In respect of a reference under section 49(5)		
(h) In respect of an application under section 55(3)		
(i) In answer to a notice of opposition under section 56(7)		
(j) In respect of a reference under section 65(3)		
(k) On contesting an application under section 76 for declaration of non- infringement		
(l) On contesting an application under section 77 for revocation of a patent		
(m) In answer to a notice of opposition under section 104(2) to the correction of an error, clerical error or mistake		
4. On application under section 20(5) or 48(3) for authorization by Registrar	\$50.00	4
5. On request for directions under section 22	\$450.00	5

6. On reference under section 23(5) or 49(5) to determine the question of licence	\$450.00	6
7. On application to the Registrar under section 24(1) 450 7 and/or 24(3)	\$450.00	7
8. On filing a statement of inventorship and of right to the grant of a patent	-	8
9. On request for early publication under section 27(2)	\$50.00	9
10. On filing a notice of withdrawal of an application for a patent under section 27(1)	-	10
11. On filing a request for a search report or a supplementary search report	\$1750.00	11
12. On filing a request for a search and examination report	\$2600.00	12
13. On furnishing information referred to in rule 46(1)	-	14
14. On filing a notice of intention to rely on an international preliminary report on patentability	-	15
15. On filing a request for an examination report	\$1100.00	16
16. On request to amend application before grant	-	17
17. On filing a response to a written opinion under section 31 or 39	-	18
18. On request that a certificate of grant be issued –		19
(a) where the application for a patent has not more than 25 claims in the patent specification when rule 49(3) is complied with	\$200.00	
(b) where the application for a patent has more than 25 claims in the patent specification when rule 49(3) is complied with	\$200.00 plus \$20.00 for Each claim in excess of 25 claims	
19. On payment of renewal fee (not including payment of back renewal fees pursuant to restoration or cancellation of entry in the register that licences are available as of right)	-	20



(a) for each year in respect of the 5th, 6th or 7th year of the patent		
(b) for each year in respect of the 8th, 9th or 10th year of the patent	\$160.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	\$270.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	\$350.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	\$450.00	
(f) for the 20th year of the patent	\$550.00	
(g) for each year after the 20th year of the patent	\$650.00	
	\$950.00	
20. On payment of an additional fee for renewal under section 35(3) –		21
(a) not exceeding one month	\$50.00	
(b) each succeeding month (but not exceeding 6 months)	\$100.00	
21. On application to amend specification after grant	\$100.00	22
22. On notice of opposition to amendment of specification after grant	\$480.00	23
23. On application for the restoration of a patent	\$500.00	24
24. On payment of additional fee on the application for the restoration of a patent	\$300.00	25
25. On filing an offer to surrender a patent	\$70.00	26
26. On notice of opposition to offer to surrender a patent	\$250.00	27
27. On application to register or give notice of a transaction, instrument or event affecting the rights in a patent or an application for a patent – for each patent or application for a patent affected by such transaction, instrument or event	\$70.00	29
28. On filing a request, in respect of one or more patents or applications for patents, for –	\$12.00	28
(a) each alteration or correction of name		



(b) each alteration or correction of address (not being an address for service)		
29. On filing a request, in respect of each patent or application for a patent, for –	\$12.00	28
(a) each alteration or correction of address for service		
(b) each correction of an error in the register or any connected document		
(c) each correction of an error of translation or transcript or clerical error or mistake in the specification of a patent, in an application for a patent or in any document filed in connection with a patent or such an application		
30. On request for the furnishing of or access to miscellaneous information –		30
(a) fee for inspecting each file or document relating to a patent or patent application	\$6.50	
(b) fee for furnishing each file or document	\$6.00	
(c) fee for photocopying each page or part thereof of any other document by the staff of the Registry	\$0.30	
(d) where the document is placed in the public search room –		
(i) fee for self-service photocopying of each page or part of the document using a stored-value card	\$0.15	
(ii) fee for photocopying of each page or part thereof by the staff of the Registry	\$0.30	
31. On request for certificate of the Registrar –		31
(a) by impressed stamp -		
(i) for the first 20 sheets	\$18.00	
(ii) for each additional sheet thereafter	\$0.30	
(b) sealed and attached to the documents -		
(i) for the first 20 sheets	\$30.00	

(ii) for each additional sheet thereafter	\$0.30	
(c) in respect of a priority document under rule 17.1(b) of the Regulations under the Patent Cooperation Treaty	\$50.00	
(d) in respect of a certified copy of the international application for a patent under rule 124	\$28.00	
32. On application for entry of order of court in the register	\$10.00	32
33. On application by proprietor for entry to be made in the register to the effect that licences under the patent are to be available as of right	\$70.00	33
34. On application for settlement of terms of licence of right	\$380.00	34
35. On application under section 56(1) or section 56(3) for cancellation of entry in the register	\$70.00	35
36. On notice of opposition to an application under section 56(1) or 56(3) for cancellation of entry in the register	\$90.00	36
37. On reference to the Registrar of a dispute as to infringement	\$280.00	37
38. On application for declaration of non- infringement	\$280.00	38
39. On application under section 77 for the revocation of a patent	\$500.00	40
40. On request for re-examination of a patent in response to the Registrar's direction	\$900.00	41
41. On request for re-examination of a patent in response to the Registrar's direction	\$160.00	42
42. On payment of prescribed fee and request for publication of translation	\$70.00	43
43. On application to Registrar for an international application for a patent (Brunei Darussalam) to be treated as an application under the Order	\$160.00	44
44. On request for the exercise of the discretionary powers of the Registrar	\$100.00	48

45. On declaration of authorisation where agent appointed or in substitution for another	\$10.00 for each patent or application for patent	46
46. On payment of the advertisement fee upon receipt of the Registrar's request under rule 97(4)	\$18.00	47
47. On notice of opposition to the correction of an error, clerical error or mistake	\$100.00	48
48. On request for information relating to a patent or an application for a patent	\$24.00	49
49. On request for extension of each time or period under rule 114(4) - for each month or part of a month for which the extension is sought	\$200.00	50
50. On request for extension of each time or period under rule 114(6)	\$200.00	52
51. On payment of additional fee for extension of each time or period under rule 114(9) – for each month, or part of a month, for which the extension is granted	\$200.00	53
52. On request for extension of periods under sections 51 29(7) and 30(1)(a) – (a) where the application is not an international application for a patent (Brunel Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	\$1800.00	
(b) where the application is an international application for patent (Brunei Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	Nil	
53. On payment of transmittal fee under rule 14 of the Regulations under the Patent Co-operation Treaty	\$150.00	54
54. On payment of fee under rule 123(6) in respect of a request under rule 26 bis.3(a) of the Regulations under the Patent Co-operation Treaty	\$250.00	-

55. On request for certificate authorising release of sample of micro-organism	\$15.00	55
56. On notice of intention to restrict availability of samples of micro-organisms to experts	\$15.00	56
57. On request for certificate authorising release of sample of micro-organism to an expert	\$15.00	57
58. On payment of renewal fee under section 55 or 56 –		58
(a) for each year in respect of the 5th, 6th or 7th year of the patent	\$80.00	
(b) for each year in respect of the 8th, 9th or 10th year of the patent	\$135.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	\$175.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	\$225.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	\$275.00	
(f) for the 20th year of the patent	\$325.00	
(g) for each year after the 20th year of the patent	\$475.00	
59. On application to extend the term of a patent under section 36	\$950.00	59
60. On filing a request for a search and examination report 60 after grant under section 39 –		60
(a) where the Examiner is the Austrian Patent Office	\$2680.00	
(b) where the Examiner is the Danish Patent and Trademark Office	\$3100.00	
(c) where the Examiner is the Hungarian Patent Office	\$2680.00	
61. On filing one or more documents under section 26(7)(c) or (8) or 28(8)	-	61

62. On filing a declaration under rule 9(2) or a request under rule 9(3)	\$120.00	62
63. On filing a request under rule 10(2)	\$250.00	62
64. On filing any miscellaneous document or documents	-	99
65. For using the patent computer facilities in the public search room of the Registry		
(a) for every half hour or part thereof of log on 2 access using the patent search terminal	\$2.00	
(b) for each sheet of information printed	\$0.30	
66. Purchase of a copy of —		
(a) Patents Journal A	\$10.00	
(b) Patents Journal B	\$36.00	



SECOND SCHEDULE

DESCRIPTIONS OF FORMS

<u>No.</u>	<u>Description of Form</u>	<u>Corresponding Form No.</u>
1	Certificate of Grant	Certificate Form 1
2	Certificate of Extension of Patent Term	Certificate Form 2
3	Request for the Grant of a Patent under section 25	Patents Form 1
4	Reference under section 20(1) or 48(1)	Patents Form 2
5	Counter statement	Patents Form 3
6	Application under section 20(5) or 48(3) for Authorisation by the Registrar	Patents Form 4
7	Request for Directions under section 22	Patents Form 5
8	Reference under section 23(5) or 48(5) to Determine the Question of a Licence	Patents Form 6
9	Application to Registrar under section 24(1) and/or 24(3)	Patents Form 7
10	Statement of Inventorship and of Right to the Grant of a Patent under section 24	Patents Form 8
11	Request for Early Publication under section 27(2)	Patents Form 9
12	Withdrawal of an Application for a Patent under section 27(1)	Patents Form 10
13	Request for a Search Report or Supplementary Search Report	Patents Form 11
14	Request for a Search and Examination Report	Patents Form 12
15	Furnishing of Prescribed Details	Patents Form 13
16	Furnishing of Prescribed Information	Patents Form 14
17	Notice of Intention to Rely on International Preliminary Report on Patentability under section 29(2)(e)(ii)	Patents Form 15
18	Request for an Examination Report	Patents Form 16
19	Request to Amend Application before Grant under section 31(2)	Patents Form 17



20	Response to Written Opinion under section 31 or 39	Patents Form 18
21	Payment of Fee for Grant of a Patent under section 30	Patents Form 19
22	Payment of Renewal Fee under section 35(2) or 56(2)	Patents Form 20
23	Payment of Additional Fee under section 35(3)	Patents Form 21
24	Application to Amend Specification after Grant under section 38	Patents Form 22
25	Notice of Opposition to Amendment of Specification after Grant under section 38 or 80	Patents Form 23
26	Application for Restoration of a Patent under section 40	Patents Form 24
27	Additional Fee on the Application for Restoration of a Patent under section 40	Patents Form 25
28	Offer to Surrender a Patent under section 41(1)	Patents Form 26
29	Notice of Opposition to Offer to Surrender a Patent under section 41(2)	Patents Form 27
30	Request for Alteration of Name, Address or Address for Service, or Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 28
31	Application to Register or to Give Notice of a Transaction, Instrument or Event Affecting the Rights in a Patent or an Application for a Patent under section 44	Patents Form 29
32	Request for Miscellaneous Information under section 43 or 105	Patents Form 30
33	Request for Certificate of the Registrar under section 46	Patents Form 31
34	Application for Entry of Order of Court in the Register under section 44	Patents Form 32
35	Application for Entry to be Made in the Register to the effect that Licences under the Patent are to be available as of Right under section 55(1)	Patents Form 33
36	Application for Settlement of Terms of a Licence of Right under section 55(3)	Patents Form 34
37	Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 35
38	Notice of Opposition to an Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 36



39	Reference to the Registrar of a Dispute as to Infringement under section 65(3)	Patents Form 37
40	Application for Declaration of Non-Infringement under section 76	Patents Form 38
41	Application for Information on Corresponding Applications for a Patent	Patents Form 39
42	Application for Revocation of a Patent under section 77	Patents Form 40
43	Request for Re-Examination of a Patent in Response to direction of the Registrar under section 77	Patents Form 41
44	Payment of Fee for Entry into National Phase under section 83(3)	Patents Form 42
45	Payment of Prescribed Fee and Request for Publication of Translation under section 83(7)	Patents Form 43
46	Application to the Registrar for an International Application to be Treated as an Application under section 82 of the Order	Patents Form 44
47	Request for the Exercise of the Registrar's Discretionary Powers under section 89	Patents Form 45
48	Declaration of Authorisation where an Agent is Appointed or where One Agent is Substituted for Another	Patents Form 46
49	Additional Fee for the Advertisement of Proposed Correction under section 104	Patents Form 47
50	Notice of Opposition to the Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 48
51	Request for Information Relating to a Patent or an Application for a Patent under section 105	Patents Form 49
52	Request for Extension of Time or Period under rule 114(4)	Patents Form 50
53	Request for Extension of Periods under sections 29 (7) and 30(1)(a)	Patents Form 51
54	Request for Extension of Time or Period under rule 114(6)	Patents Form 52
55	Additional Fee for Extension of Time or Period under rule 114(9)	Patents Form 53



56	Payment of Transmittal Fee under rule 14 of the Regulations under the Patent Co-Operation Treaty	Patents Form 54
57	Request for Certificate Authorising Release of Sample of Micro-Organism	Patents Form 55
58	Notice of Intention to Restrict Availability of Samples of Micro-Organisms to Experts	Patents Form 56
59	Request for Certificate Authorising Release of Sample of Micro-Organisms to an Expert	Patents Form 57
60	Payment of Renewal Fee pursuant to section 55(3)(d)	Patents Form 58
61	Request for an Extension of the Term of a Patent under section 36	Patents Form 59
62	Request for Search and Examination after Grant under section 39	Patents Form 60
63	Filing of Documents under section 26(7)(c) or (8) or 28(8)	Patents Form 61
64	Declaration under rule 9(2) or Request under rule 9(3) or 10(2)	Patents Form 62
65	Filing of Miscellaneous Document or Documents	Patents Form 99



THIRD SCHEDULE

SCALE OF COSTS

PART I

BASIC COST

<i>Item</i>	<i>Matter</i>	<i>Amount</i>
1	Drawing and filing notice of opposition or application for revocation together with statement of case	\$200.00
2	Drawing and filing a counter-statement	\$150.00
3	Preparing and lodging evidence for a notice of opposition, an application for revocation or a counter-statement	\$200.00 - \$800.00
4	Perusing a notice of opposition, an application for revocation or a counter-statement (per folio)	\$2.00 per folio
5	Preparing for all interlocutory proceedings	\$25.00 - \$120.00
6	Attending all interlocutory proceedings	\$25.00 - \$50.00
7	Preparing for hearing	\$500.00 - \$1500.00
8	Attendance at hearing by patent agent without advocate or solicitor	\$100.00 per hour up to a maximum of \$450.00 per day
9	Attendance at hearing by patent agent with instructing advocate or solicitor	\$60.00 per hour up to a maximum of \$270.00 per day
10	Advocate or Solicitor fees	\$120.00 per hour up to a maximum of \$540.00 per day
11	Drawing bill of costs (per folio)	\$2.00 per folio
12	Attending taxation, and obtaining the Registrar's certificate or order	\$50.00 - \$120.00



PART II

ADDITIONAL COSTS

1. A person who has paid a fee prescribed in these Rules in relation to proceedings before the Registrar shall be paid the amount of the fee.
2. A person attending proceedings before the Registrar shall be paid –
 - (a) a reasonable amount for expenses incurred for transport between the usual place of residence of the person and the place that he attends for that purpose; and
 - (b) if the person is required to be absent overnight from his usual place of residence, a reasonable amount as allowances up to a daily maximum of \$250 for meals and accommodation.
3. A person who, because of his professional, scientific or other special skill or knowledge, is summoned to appear before the Registrar as a witness shall be paid –
 - (a) if the person is remunerated in his occupation by wages, salary or fees, an amount equal to the amount of wages, salary or fees not paid to the person because of his attendance before the Registrar for that purpose, but such amount should not exceed \$150 per day; or
 - (b) in any other case, an amount of not less than \$100 but not more than \$150 for each day on which he so attends.



FOURTH SCHEDULE

MICRO-ORGANISMS

Applications.

1. (1) The specification of an application for a patent, or of a patent, for an invention which requires for its performance the use of a micro-organism –

- (a) which is not available to the public at the date of filing of the application; and
- (b) which cannot be described in the specification in such a manner as to enable the invention to be performed by a person skilled in the art, shall, in relation to the micro-organism itself, be treated for the purposes of the Order as disclosing the invention in such a manner only if one of the conditions set out in subparagraph (2), is satisfied.

(2) The conditions referred to in sub-paragraph (1) are –

- (a) a condition that –
 - (i) not later than the date of filing of the application, a culture of the micro-organism has been deposited with any international depositary authority which is able to furnish a sample of the micro-organism; and
 - (ii) the name of the international depositary authority, the date when the culture was deposited and the accession number of the deposit are given in the specification of the application; and
- (b) a condition, in the case of an international application for a patent (Brunei Darussalam) which is treated, by virtue of section 85 as a patent under the Order, or, as the case may be, an application for a patent under the Order, that the corresponding provisions of the Implementing Regulations to the Patent Co-operation Treaty have been complied with, and where a new deposit is made under paragraph 4, a further condition that the applicant or proprietor makes a new deposit in accordance with that paragraph.

(3) Where the condition of sub-paragraph (2)(a)(ii) is not satisfied at the time the application for a patent is filed, it shall be satisfied –

- (a) within 16 months from –
 - (i) the declared priority date; or
 - (ii) the date of filing the application where there is no declared priority date;
- (b) where, on a request made by the applicant, the Registrar publishes the application before the end of the period prescribed for the purposes of section 27(1), before the



date of the request; or

- (c) where the Registrar sends notification to the applicant that, in accordance with section 105(4), he has received a request by any person for information and inspection of documents under subsection (1) of that section, before the end of one month after his sending to the applicant notification of his receipt of the request, whichever is the earliest.
- (4) The giving of the information specified in sub-paragraph (2)(a)(ii) shall constitute the unreserved and irrecoverable consent of the applicant to the international depositary authority with which a culture (including a deposit which is to be treated as having always been available by virtue of paragraph 4(2)) is from time to time deposited making the culture available on receipt of the Registrar's certificate authorising the release to the person who is named therein as a person to whom the culture may be made available and who makes a valid request therefor to the authority.

Availability of cultures.

- 2. (1) Subject to paragraph 3, a request that the Registrar certify a person as a person to whom an international depositary authority may furnish a sample of a micro-organism –
 - (a) before publication of the application for a patent, to a person who has made a request under section 105(1) in the circumstances mentioned in paragraph 1(3)(c); and
 - (b) at any later time, to any person, shall be made on Patents Form 55 together with the form provided for by the Regulations under the Budapest Treaty.
- (2) The Registrar shall send a copy of any form lodged with him under subparagraph (1) and of his certificate authorising the release of the sample –
 - (a) to the applicant for, or proprietor of, the patent;
 - (b) to the international depositary authority; and (c) to the person making the request.
- (3) A request under sub-paragraph (1) shall comprise, on the part of the person to whom the request relates, undertakings for the benefit of the applicant for, or proprietor of, the patent –
 - (a) not to make the culture, or any culture derived from it, available to any other person; and
 - (b) not to use the culture, or any culture derived from it, otherwise than for experimental purposes relating to the subject matter of the invention, and –
 - (i) subject to sub-paragraph (iii), both undertakings shall have effect during any period before the application for a patent has been withdrawn, has been treated as having been abandoned, has been refused or is treated as having been refused (including any further period allowed under rule 110, 120(1) or (6) but excluding,



where an application is reinstated under either of those rules, the period before it is reinstated);

- (ii) if a patent is granted on the application, the undertaking set out in sub-paragraph (a) shall also have effect during any period for which the patent is in force and during the period of 6 months referred to in section 35(3); and
- (iii) the undertaking set out in sub-paragraph (b) shall not have effect after the date of publication in the journal of a notice that the patent has been granted, and, in this sub-paragraph, references to a culture derived from a deposited culture of a microorganism are references to a culture so derived which exhibits those characteristics of the deposited culture essential for the performance of the invention.

(4) For the purpose of enabling any act specified in section 59 to be done in relation to the culture for the services of the Government, the undertakings specified in subparagraph (3) –

- (a) shall not be required from any Government department or person authorised in writing by a Government department for the purposes of this paragraph; and
- (b) shall not have effect in relation to any such person who has already given them.

(5) An undertaking given pursuant to sub-paragraph (3) may be varied by way of derogation by agreement between the applicant or proprietor and the person by whom it is given.

(6) Where, in respect of a patent to which the undertaking set out in sub-paragraph (3)(a) has effect –

- (a) an entry is made in the register under section 55 to the effect that licences are to be available as of right; or
- (b) a compulsory licence is granted under section 57, that undertaking shall not have effect to the extent necessary for effect to be given to any such licence.

Availability of cultures to experts.

3. (1) Subject to sub-paragraph (3), where, before the preparations for publication under section 27 of an application for a patent have been completed, the applicant gives notice to the Registrar on Patents Form 56 of his intention that a sample of the microorganism should be made available only to an expert, the provisions of this paragraph shall have effect.

(2) The Registrar –

- (a) shall, at the time of publication of the application under section 27, publish a notice in the journal that the provisions of this paragraph have effect; and
- (b) notwithstanding paragraph 2, shall not, until the patent is granted or the application has been withdrawn, has been treated as having been abandoned, has been refused or is



treated as having been refused, issue any certificate authorising release of a sample otherwise than under this paragraph.

(3) In the case of an international application for a patent (Brunei Darussalam), the applicant may, for the purpose set out in sub-paragraph (1), give notice in writing to the International Bureau under rule 13 bis 3 of the Regulations under the Patent Co-operation Treaty before the technical preparations for international publication of the application are complete of his intention that a sample of the micro-organism should be made available only to an expert and he shall be treated by the Registrar for the purposes of this paragraph as having complied with the conditions in sub-paragraph (1) and sub-paragraph (2)(a) shall not apply.

(4) Any person wishing to have a sample of the micro-organism made available ("the requester") –

(a) shall apply to the Registrar on Patents Form 57 together with the form provided for by the Regulations under the Patent Co-operation Treaty nominating the person ("the expert") to whom he wishes the sample to be made available; and

(b) shall at the same time file undertakings by the expert as set out in paragraph 2 (3) in accordance with the provisions of that paragraph.

(5) The Registrar shall send a copy of Patents Form 57 filed under sub-paragraph (4) to the applicant for the patent and shall specify the period within which the applicant may object, in accordance with sub-paragraph (6), to a sample of the micro-organism being available to the expert.

(6) Unless, within the period specified by the Registrar under sub-paragraph (5) (or within such longer period as the Registrar may, on application made to him within that period, allow), the applicant for the patent sends notice in writing to the Registrar that he objects to a sample of the micro-organism being made available to the expert and gives his reasons for his objection, the Registrar shall send a copy of any form lodged with him under sub-paragraph (4)(a) and of his certificate authorising the release of the sample –

(a) to the applicant for the patent;
(b) to the international depositary authority concerned;
(c) to the requester; and
(d) to the expert.

(7) Where, in accordance with sub-paragraph (6), the applicant for the patent sends notice to the Registrar of his objection to the issue of a certificate in favour of the expert, the Registrar –

(a) shall decide, having regard to the knowledge, experience and technical qualifications of the expert and to any other factors he considers relevant, whether to issue his certificate in favour of the expert; and

(b) if he decides to authorise the release of the sample to the expert, shall send to the persons



referred to in sub-paragraph (6) a copy of any form lodged with him under subparagraph (4)(a) and of his certificate authorising the release of the sample to the expert.

(8) Before making a decision in accordance with sub-paragraph (7), the Registrar shall afford the applicant and the requester the opportunity of being heard.

(9) If the Registrar decides under sub-paragraph (7) not to issue his certificate in favour of the expert, the requester may, by notice in writing to the Registrar and the applicant, nominate another person as the expert for the purposes of this paragraph; and the Registrar shall give such directions as he may think fit with regard to the subsequent procedure.

(10) Nothing in this paragraph shall affect the rights under section 58 of any Government department or of any person authorised in writing by a Government department.

New deposits.

4. (1) Where the international depositary authority with which a deposit or a new deposit of a culture has been made under this Schedule –

(a) notifies the applicant or proprietor that it –

(i) cannot satisfy a request made in accordance with paragraph 2(1) or 3(4); or

(ii) is not able lawfully, to satisfy such a request, for the culture to be made available;

(b) ceases temporarily or permanently to carry out the functions of an international depositary authority; or

(c) ceases for any reason to conduct its activities as an international depositary authority in an objective and impartial manner, subject to sub-paragraph (3), the applicant or proprietor may, unless the culture has been transferred to another international depositary authority which is able to make it available, make a new deposit of a culture of the micro-organism.

(2) For the purposes of paragraph 1 and this paragraph, the deposit shall be treated as always having been available if, within 3 months of the receipt of such notification or of the international depositary authority ceasing to perform the functions of an international depositary authority or to conduct its activities as such an authority in an objective and impartial manner, the applicant or proprietor –

(a) in a case where the deposit has not already been transferred, makes the new deposit;

(b) furnishes to the international depositary authority with which the new deposit is made a declaration that the culture so deposited is of the same microorganism as was the culture originally deposited; and



(c) requests amendment of the specification under section 31 or 38, as the case may be, so as to indicate the accession number of the transferred or new deposit and, where applicable, the name of the international depositary authority with which the deposit has been made.

(3) The new deposit referred to in sub-paragraph (1) –

(a) shall, subject to sub-paragraph (b), be made with the same international depositary authority as was the original deposit; or

(b) in the cases referred to in sub-paragraphs (1)(a)(ii), (b) and (c), shall be made with another international depositary authority which is able to satisfy the request.

Interpretation.

5. In this Schedule –

"Budapest Treaty" means the Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure done at Budapest in 1977; "depositary institution" means an institution which, at all relevant times –

(a) carries out the functions of receiving, accepting and storing microorganisms and the furnishing of samples thereof; and

(b) conducts its affairs in so far as they relate to the carrying out of those functions in an objective and impartial manner;

"international depositary authority" means a depositary institution which has acquired the status of international depositary authority as provided in Article 7 of the Budapest Treaty.



FIFTH SCHEDULE

REMUNERATION OF SCIENTIFIC ADVISERS

1. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order and who attends the proceedings before the Registrar shall be paid –
 - (a) a reasonable amount for expenses incurred for transport between his usual place of residence and the place where the proceedings take place; and
 - (b) if the scientific adviser is required to be absent overnight from his usual place of residence, a reasonable amount as allowance for meals and accommodation up to a daily maximum of \$250.
2. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order shall, apart from the expenses and allowances referred to in paragraph 1, be paid an amount of not less than \$650 but not more than \$2,000 for each day or part thereof for which he hears the case or works on the report pursuant to an inquiry referred to him under rule 119(1)(b).
3. A person appointed as a scientific adviser to sit with the Registrar at the hearing of any proceedings may, apart from the expenses and allowances referred to in paragraph 1, be paid an amount not less than \$650 but not more than \$2,000 if he is subsequently not required to hear the proceedings with the Registrar.



**REGISTRAR OF PATENT
BRUNEI DARUSSALAM**

PATENTS RULES [S 11/2013]

NEW PATENT APPLICATION

[21]	BN/N/2022/0135	[22]	14/11/2022
[54]	Sars-Cov-2 Antibodies And Methods Of Selecting And Using The Same		
[71]	ASTRAZENECA UK LIMITED of 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 OAA, United Kingdom		
[72]	1. ESSER, Mark 2. STEINHARDT, James 3. MCTAMNEY II, Patrick 4. LOO, Yueh-Ming 5. VARKEY, Reena M. 6. DU, Qun 7. RAJAN, Saravanan		
[74]	Messrs. AIP Law of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.		
[31][32][33]	No. 63/025,463 Date: 17/05/2020 Country: United States of America		
[86]	PCT/EP2021/063008		
[87]	WO/2021/233834		
[51]	A61P 31/14, C07K 16/10		
[57]	The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and selecting the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2 infection in subject.		




FIG. 3

[21] BN/N/2022/0136 [22] 14/11/2022

[54] **Extended Time Action Acylated Insulin Compounds**

[71] **ELI LILLY AND COMPANY** of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America

[72] **1. BRENNAN, Seamus Patrick**
2. FLORA, David Benjamin
3. KISSELEV, Valdislav
4. LIU, Wen
5. VALENZUELA, Francisco Alcides

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD** of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]
No. 63/025,463 Date: 15/05/2020 Country: United States of America

[86] PCT/US2021/032144

[87] WO/2021/231676

[51] A61K 38/28, A61P 3/10, A61K 47/54, C07K 14/62

[57] The presently described compounds relate to the treatment of Type I and /or Type II diabetes and/or hyperglycemia. More particularly, the described compounds relate to extended time action acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated



insulin compounds.

[21] BN/N/2022/0137 [22] 14/11/2022

[54] Antibody Drug Conjugate, Preparation Method Therefor And Use Thereof

[71] SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD of No.666, Xinhua Avenue (Section 2) Hai Xia Industrial Park, Wenjiang District Chengdu, Sichuan 611138 China

[72] 1. XIAO, Liang
2. XUE, Tongtong
3. WANG, Jingyi
4. WANG, Cheng
5. LIU, Dengnian
6. TIAN, Qiang
7. SONG, Shuai

[74] Messrs. Spruson & Ferguson (Asia) Pte Ltd of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]
No. 202010410633.5 Date: 15/05/2020 Country: China

[86] PCT/CN2021/093348

[87] WO/2021/228141

[51] A61K 31/4745, A61K 45/06, A61K 49/00, A61K 51/10, A61P 35/00

[57] An anti-CLDN18.2 antibody-drug conjugate, a preparation method therefor and a use thereof. The antibody-drug conjugate and a composition that contains the conjugate can effectively bind to CLDN18.2 and inhibit the growth of CLDN18.2 positive tumors. The present invention further relates to a pharmaceutical composition that comprises the antibody-drug conjugate or the composition, and a use of the pharmaceutical composition in the preparation of a drug for preventing and/or treating tumors.




图 12A

AA Tumor volume (mm³)
BB Treatment duration (days)

[21] BN/N/2022/0138 [22] 16/11/2022

[54] **Compositions And Methods Of Modulating Short-Chain Dehydrogenase Activity**

[71] **Rodeo Therapeutics Corporation of 2815 Eastlake Avenue East, Suite 300 Seattle, WA 98102 United States of America**
Board Of Regents Of The University Of Texas System of 210 West 7th Street Austin, TX 78701 United States of America
Case Western Reserve University of 10900 Euclid Avenue Cleveland, OH 44106 United States of America

[72] **1. GWALTNEY, Stephen, L.**
2. READY, Joseph
3. ANTCZAK, Monika
4. MARKOWITZ, Sanford, D.
5. DESAI, Amar
6. GERSON, Stanton

[74] **Messrs. Spruson & Ferguson (Asia) Pte Ltd of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]
No. 63/027,557 Date: 20/05/2020 Country: United States of America

[86] PCT/US2021/033170



[87] WO/2021/236779

[51] A61P 1/04, A61P 1/16, A61P 5/44, A61P 9/00, A61P 13/12, A61P 29/00, A61P 35/00, A61P 35/02, C07D 495/04, C07D 519/00, A61K 31/513, A61K 31/517, A61K 31/4985, A61K 31/519, A61K 31/437, A61K 31/4375, A61K 31/5383, A61K 31/506

[57] Compounds and methods of modulating 5-PGDIT activity, modulating tissue prostaglandin levels. treating disease. diseases disorders. or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

[21] BN/N/2022/0139 [22] 17/11/2022

[54] Shiftable Covers, Completion Systems, And Methods To Shift A Downhole Cover In Two Directions

[71] HALLIBURTON ENERGY SERVICES, INC. of 3000 N. SAM HOUSTON PKWY E., HOUSTON, TEXAS 77032, United States of America

[72] 1. MACEK, Mark D.
2. DELZELL, Christopher R.

[74] Messrs. Henry Goh & Co. Sdn. Bhd of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]
No. 16/945,380 Date: 31/07/2020 Country: United States of America

[86] PCT/US2020/045049

[87] WO/2022/025937

[51] E21B 34/14, E21B 34/10, E21B 23/04

[57] The disclosed embodiments include shiftable covers, completion systems, and methods to shift a downhole cover in two directions. A shiftable cover includes a hollow interior configured to receive a diverter flowing in a first direction. The shiftable cover also includes a diverter seat disposed in the hollow interior and configured to retain the diverter. The shiftable cover also includes a plurality of segments configured to collapse in response to shifting of the shiftable cover from a first position to a second position to retain the diverter, and un-collapse in response to shifting of the shiftable cover from the second position towards the first position.




FIG. 2A

[21] BN/N/2022/0140 [22] 21/11/2022

[54] **Cyclobutyl Dihydroquinoline Sulfonamide Compounds**

[71] **AMGEN INC. of One Amgen Center Drive, M/S 28-5-A Thousand Oaks, California 91320-1799, United States of America**

[72] **1. MILGRAM, Benjamin C.
2. MARX, Isaac E.
3. WANG, Haoxuan
4. CHERNEY, Elsa D.**

[74] **Messrs. Spruson & Ferguson (Asia) Pte Ltd of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]
No. 63/037,001 Date: 10/06/2020 Country: United States of America

[86] PCT/US2021/036896


[87] WO/2021/252820

[51] C07D 215/36, A61K 31/4704, C07D 401/12, A61P 29/00, C07D 413/12

[57] **The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I), an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the**



treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.



[21]	BN/N/2022/0141	[22]	26/11/2022
[54]	A Prayer Garment		
[71]	SITCA DESIGNS SDN. BHD. of 16-A (1st Floor), Jalan Tun Sambanthan 3, Brickfields, 50470 Kuala Lumpur, Malaysia		
[72]	1. Shazmin Hashim binti Zainal		
[74]	Messrs. CCW Partnership of 1st & 2nd Floors, Units 9 & 10 Block C, Kiarong Complex, Lebuhraya Sultan Hassanal Bolkiah BE1318, Brunei Darussalam		
[31][32][33]			
No. UI2022003669 Date: 08/07/2022 Country: Malaysia			
[57]	A PRAYER GARMENT Abstract A prayer garment for a Muslimah, comprising a head cover having a face opening; and a loose-fitting garment extending from one end of the head cover to a ground configured to cover a torso and each limb of the muslimah, wherein the loose-fitting garment having a length adjustment means that pulls a portion of the torso section in a vertical direction relative to the length adjustment means such that a portion of a foot end of the loose-fitting garment no longer contacts the ground. 10 Ref. Fig: Fig. 1 15 20 25		



[21] BN/N/2022/0142 [22] 14/11/2022

[54] **Pcsk9 Inhibitors And Methods Of Use Thereof To Treat Cholesterol-Related Disorders**

[71] **Amgen Inc. of One Amgen Center Drive, Thousand Oaks, California 91320-1799 United States of America**

[72] 1. HAMER, Andrew W.
2. BRIDGES, Ian Matthew
3. WANG, Huei
4. RUZZA, Andrea
5. KURTZ, Christopher

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**


[31][32][33]
No. 63/032.451 Date: 29/05/2020 Country: United States of America

[86] PCT/US2021/034489

[87] WO/2021/243002

[51] C07K 16/40

[57] **Methods of lowering LDL cholesterol in a pediatric subject having a cholesterol-related disorder, e.g., heterozygous familial hypercholesterolemia (HeFH). by administering a PCSK9 inhibitor are provided.**





[21] BN/N/2022/0143 [22] 30/11/2022

[54] Method For Preparing Mdi And Method For Preparing Phosgene

[71] WANHUA CHEMICAL GROUP CO., LTD. of No. 17, Tianshan Rd, YEDA Yantai, Shandong 264006, China
WANHUA CHEMICAL (NINGBO) CO., LTD. of Wanhua Industrial Park, Daxie Development Zone, 39 Huandao Road (North), Ningbo, Zhejiang 315812, China

[72] 1. WEN, Fang
2. WANG, Zhenyou
3. ZHAO, Dongke
4. CHEN, Liangjin
5. XU, Dan
6. DONG, Chao
7. ZHANG, Hongke
8. WU, Xuefeng

[74] Messrs PINTAS IP GROUP SDN BHD of MIA Management Services P.O. Box 18, Anggerek Desa Complex, BB3780, Brunei Darussalam.

[31][32][33]
No. 63/025,463 Date: 15/05/2020 Country: United States of America

[86] PCT/CN2020/113112

[87] WO/2022/047681

[51] B01J 21/18, B01J 27/224, C01B 32/80, C07C 263/10, C07C 265/14

[57] The present invention provides a method for preparing MDI and a method for preparing phosgene. The method for preparing MDI provided by the present invention comprises: in the presence of a solvent, subjecting a phosgene feedstock and MDA to a phosgenation reaction in a phosgenation reactor to generate reaction products comprising the MDI and hydrogen chloride, and discharging the hydrogen chloride from the phosgenation reactor as a discharged gaseous phase to control the mass content of high-boiling 't(point chlorinated hydrocarbon impurities contained in the phosgene feedstock for the phosgenation reaction to be less than 1,000 ppm, I the high-boiling point chlorinated hydrocarbon impurities being saturated and/or unsaturated chlorinated hydrocarbons with two carbon atoms. The method for preparing MDI provided by the present invention has improved process stability.



[21] BN/N/2022/0145 [22] 01/12/2022

[54] **Crf1 Receptor Antagonist For The Treatment Of Congenital Adrenal Hyperplasia**

[71] Neurocrine Biosciences, Inc. of 12780 El Camino Real San Diego, California 92130
United States of America
SANOFI of 46 avenue de la Grande Armée 75017 Paris France

[72] 1. FARBER, Robert H.
2. CHAN, Jean L.
3. ROBERTS, Eiry
4. CUTLER, JR., Gordon B.
5. NAKANISHI, Arline
6. CHARLIER, Anne
7. LOEWEN, Gordon RAPHAEL
8. ZHANG, Xiaoping
9. GIRI, Nagdeep
10. STIRN, Scott
11. SAYERS, Brian
12. TAYLOR, Graeme
13. COSTA, Christina MARIE
14. PARK, Stacy
15. VICKERY, Anthony D.
16. DOWNING, Kristie M.
17. IYoha, Kingsley
18. NGWENYA-JONES, Ayanda
19. MEHTON, Gurvinder

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]
No. 2006039 Date: 10/10/2020 Country: France

[86] PCT/US2021/036668

[87] WO/2021/252669

[51] A61K 31/426, A61K 31/573, A61P 5/38, A61K 9/00

[57] Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering to the subject a compound of Formula (I): [INSERT FORMULA] (I), or a pharmaceutically acceptable salt thereof,



[21] BN/N/2022/0146 [22] 06/12/2022

[54] Apparatus And Method For Testing A Fire Suppression System

[71] PARADIGM FLOW SERVICES LIMITED of 5 Carden Place, Aberdeen AB10 IUT, United Kingdom

[72] 1. MACKENZIE, Hugh
2. THOMSON, Ashley

[74] Messrs. MARKS&CLERK SINGAPORE LLP of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]
No. 2008644.3 Date: 08/06/2020 Country: United Kingdom

[86] PCT/GB2021/051413

[87] WO/2021/250389

[51] A62C 35/62, A62C 37/50

[57] An apparatus (10) for testing a water deluge system (12) having a wet side (16) and a dry side (14) separated by a valve (18) comprises a blower (24) configured for coupling to an inlet (42) of the water deluge system (12). The blower (24) is configured to provide a supply of pressurised air through the water deluge system (12) from the inlet (42) to one or more outlet of the water deluge system (12). A sensor arrangement (26) is coupled to or operatively associated with one or more of the outlets (22) of the water deluge system (12), and is configured to measure the pressure of the air at the one or more outlets (22) of the water deluge system (12) and then output one or more output signals indicative of the pressure of the air at the one or more outlets (22). A communication arrangement (34) conveys the one or more output signals from the sensor arrangement (26) to a processing system configured to determine from said one or more output signals the flow rate of the air supply at the one or more outlets (22).




FIG. 1

[21] BN/N/2022/0147 [22] 10/12/2022

[54] **Heat Engine And Method Of Manufacture**

[71] **KATRICK TECHNOLOGIES LIMITED of The Garment Factory, Suite 8, 10 Montrose Street, Glasgow G1 1RE, United Kingdom**

[72] **1. VELAYUTHAM, Karthikeyan**

[74] **Messrs. AIP LAW of Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]
No. 2008912.4 Date: 11/06/2020 Country: United Kingdom

[86] PCT/GB2020/053348

[87] WO/2021/250365

[51] **F01K 7/02, F01K 25/06, F01K 27/00**

[57] **A heat engine is disclosed. The heat engine comprises a housing (1), a first liquid (3) and a second liquid (4) located within the housing (1). The first liquid (3) has a higher density and lower boiling point than the second liquid (4). The heat engine further comprises a heat exchanger (6) which transfers heat to the first liquid (3) to evaporate the first liquid (3) to form a first liquid vapour (20). The heat engine also comprises at least one fluid flow member (9) which moves in response to a fluid flow created by the interaction of the first liquid vapour (20) and the second liquid (4). The liquid-gas phase change of the first fluid provides an alternative mechanism for converting heat into work with numerous advantages. The heat engine has minimal moving parts, a relatively long lifetime, does not require a specific fuel, does not directly release toxic or unenvironmentally friendly gases, and can be adapted to a specific source of waste heat.**




Figure 3

[21] BN/N/2022/0148 [22] 12/12/2022

[54] Gene Sequencing Analysis Method And Apparatus, Storage Medium, And Computer Device

[71] BGI GENOMICS CO., LTD. of Floors 7-14, Building No. 7, BGI Park, No. 21 Hongan 3rd Street, Yantian District, Shenzhen, Guangdong 518083 China

[72] 1. YANG, Jiaobo
2. JIN, Xiangqian
3. HE, Zengquan
4. ZHANG, Youjin

[74] Messrs. HENRY GOH & CO SDN BHD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]
No. 202110698855.6 Date: 23/06/2021 Country: China

[86] PCT/CN2022/097102


[87] WO/2022/267867

[51] G16B 30/00, G16B 50/00, G06F 9/50

[57] In the gene sequencing analysis method and apparatus, storage medium, and computer device provided by the present disclosure, short sequences transmitted from a sequencing platform in real time are first sliced to perform corresponding slicing processing, and then the slice data is input into a memory. Thus, a pre-loaded encapsulation program in the memory can be called to perform bioinformatic analysis on the slice data, thereby obtaining a corresponding analysis result. Such a process can acquire the slice data of the sequencing of the sequencing platform in real time and perform sequencing and analysis on the slice data, rather



than performing the processing analysis only after the sequencing platform has finished the sequencing and the complete sequencing results are transmitted to the corresponding platform. Therefore, the present disclosure enables the whole of sequencing and analysis to be accelerated. In addition, the data for analysis is the slice data, which can be transmitted faster and takes less time compared with the whole sequencing result.



[21] BN/N/2022/0149 [22] 12/12/2022

[54] Catalytic Cracking Additive, Preparation Method Therefor, And Application Thereof

[71] CHINA PETROLEUM & CHEMICAL CORPORATION of 22 CHAOYANGMEN NORTH STREET, CHAOYANG DISTRICT, BEIJING 100728, CHINA
RESEARCH INSTITUTE OF PETROLEUM PROCESSING, SINOPEC of 18 XUEYUAN ROAD, HAIDIAN DISTRICT, BEIJING 100083, CHINA

[72] 1. YU, Shangqing
2. YAN, Jiasong
3. ZHANG, Jiexiao
4. LIN, Wei

[74] Messrs. HENRY GOH & CO SDN BHD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]
No. 202010555732.2 Date: 17/06/2020 Country: China

[86] PCT/CN2021/100467

[87] WO/2021/254410

[51] B01J 29/76, B01J 29/70, B01J 29/80, B01J 29/06, C10G 11/05, C10G 11/04, C10G



11/02, C07C 4/06, C01B 39/02

[57] Disclosed is a catalytic cracking additive, its preparation and application thereof, wherein the catalytic cracking additive comprises 10-50 wt% of a modified 0 zeolite, 20-85 wt% of a clay and 5-35 wt% of a boron-containing binder, based on the total weight of the catalytic cracking additive; the modified 0 zeolite comprises 0.1-1 wt% of CuO and 1-15 wt% of P2O5, and has a micro-activity index of at least 58; the boron-containing binder comprises 70-97 wt% of Al2O3 and 3-30 wt% of B2O3, and has a pH value of 1.0-3.5. The catalytic cracking additive can significantly improve the yield of C4 olefins and the concentration of C4 olefins in liquefied gas.

[21] BN/N/2022/0150 [22] 13/12/2022

[54] **Quinoxaline Derivatives As Anti-Cancer Drugs**

[71] **ASTRAZENECA AB of 151 85 Södertälje, Sweden**

[72] **1. PACKER, Martin, John
2. DEGORCE, Sebastien, Louis
3. JOHANNES, Jeffrey, Wallace
4. HANDE, Sudhir, Mahadeo
5. GHOSH, Avipsa
6. ZHENG, Xiaolan**

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**


[31][32][33]
No. 63/044,095 Date: 25/06/2020 Country: United States of America
No. 63/120,351 Date: 02/12/2020 Country: United States of America

[86] **PCT/EP2021/067304**

[87] **WO/2021/260092**

[51] **C07D 401/12, A61K 31/496, A61P 35/00**

[57] **The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine.**





[21] BN/N/2022/0151 [22] 13/12/2022

[54] 2-0x0imidazolidine-4-Carboxamides As Nav1.8 Inhibitors

[71] Merck Sharp & Dohme LLC of 126 East Lincoln Avenue Rahway, New Jersey 07065 United States of America

[72] 1. ARASAPPAN, Ashok
2. BELL, Ian, M.
3. BUNGARD, Christopher, James
4. BURGEY, Christopher, S.
5. COX, Jason, M.
6. KELLY, Michael, J.
7. LAYTON, Mark, E.
8. LIU, Hong
9. LIU, Jian
10. PERKINS, James, J.
11. SHAH, Akshay
12. VANHEYST, Michael, David
13. WU, Zhe

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.


[31][32][33]
No. 63/040,461 Date: 17/06/2020 Country: United States of America

[86] PCT/US2021/037303

[87] WO/2021/257490

[51] C07D 233/32, C07D 401/12, C07D 403/12, C07D 405/12, C07D 413/12, C07D 417/12, C07D 417/14, C07D 471/04, C07D 513/04

[57] Novel compounds of the structural formula (I). and the pharmaceutically acceptable salts thereof, are inhibitors of Nav 1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav 1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.



(I)

[21] BN/N/2022/0152 [22] 15/12/2022

[54] **Acalabrutinib Maleate Dosage Forms**

[71] **ACERTA PHARMA B.V. of Kloosterstraat 9, 5349 AB Oss, Netherlands**

[72] **1. BETHEL, Paul
2. BLYTH, John
3. COSGROVE, Steve
4. GOLDEN, Michael
5. MANN, James
6. PEPIN, Xavier, Jacques, Henri
7. ROBBINS, Andrew
8. SIMPSON, David**

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]
No. 63/041,197 Date: 19/06/2020 Country: United States of America

[86] PCT/EP2021/066629

[87] WO/2021/255246

[51] A61K 9/20, A61K 31/4985, A61K 9/16, A61P 35/02

[57] **The present disclosure relates, in general, to: (a) solid pharmaceutical dosage forms comprising acalabrutinib maleate; (b) methods of using such pharmaceutical dosage forms to treat B-cell malignancies and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods.**



[21] BN/N/2022/0153 [22] 19/12/2022

[54] **Antibodies That Bind Tgf-Alpha And Epiregulin For Use In The Treatment Of Pain**

[71] **ELI LILLY AND COMPANY** of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America

[72] 1. CHEDID, Marcio
2. HEUER, Josef G.

[74] Messrs. Spruson & Ferguson (Asia) Pte Ltd of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]
No. 63/044,455 Date: 26/06/2020 Country: United States of America
No. 63/070,507 Date: 26/08/2020 Country: United States of America

[86] PCT/US2021/038394

[87] WO/2021/262662

[51] A61P 25/00, C07K 16/22

[57] The present invention provides for therapeutic use of antibodies that bind human TGF- alpha and human Epiregulin in the treatment of chronic pain, and in particular chrome ostcoarthritis pain, chronic diabetic neuropath pain, or chronic low back pain.

[21] BN/N/2022/0154 [22] 20/12/2022

[54] **High Affinity Antibodies Targeting Tau Phosphorylated At Serine 413**

[71] **Merck Sharp & Dohme LLC** of 126 East Lincoln Avenue Rahway, New Jersey 07065, United States of America

[72] 1. BAKER, Jeanne
2. PARMENTIER BATTEUR, Sophie
3. CHEN, Ming-Tang
4. CHENG, Alan, C.
5. HSIEH, Chung-Ming



**6. MIECZKOWSKI, Carl
7. SUON, Sokreine**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]

No. 63/044,291 Date: 25/06/2020 Country: United States of America

[86] PCT/US2021/038591

[87] WO/2021/262791

[51] A61K 39/395, C07K 16/18, A61P 25/28, A61K 39/00

[57] **Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.**




FIG.4E

[21] BN/N/2022/0155 [22] 20/12/2022

[54] **Multi-Specific Antibodies Binding To Bcma**

[71] **Teneobio, Inc. of One Amgen Center Drive, Thousand Oaks, California 91320 United States of America**

[72] **1. TRINKLEIN, Nathan
2. HARRIS, Katherine
3. MALIK, Harbani**



- 4. SCHELLENBERGER, Ute**
- 5. VAFA, Omid**
- 6. FORCE ALDRED, Shelley**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]

No. 63/046,477 Date: 30/06/2020 Country: United States of America

[86] **PCT/US2021/039961**

[87] **WO/2022/006316**

[51] **A61P 35/00, A61K 35/17, C07K 14/725, C07K 16/18, C07K 16/28**

[57] **Multi-specific, human heavy chain antibodies (e.g., UniAbsTM) binding to BCMA are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of BCMA.**

FIG. 1

Name	CDR1	CDR2	CDR3
BCMA heavy chain-only CDR sequences	GFTFSSNA (SEQ ID NO: 1)	ISGSGDYT (SEQ ID NO: 2)	AKEVPGGPLVDFDS (SEQ ID NO: 3)
La protein, v. 1, heavy chain CDR sequences	GYTFTHYY (SEQ ID NO: 4)	VNPSNGGT (SEQ ID NO: 5)	ARSEYDYGLGFAY (SEQ ID NO: 6)
La protein, v. 2, heavy chain CDR sequences	GYAFTHYY (SEQ ID NO: 7)	VNPSNGGT (SEQ ID NO: 5)	TRSEYDYGLGFAY (SEQ ID NO: 8)
La protein light chain CDR sequences	QSLLNSRTPKNY (SEQ ID NO: 9)	WAS (SEQ ID NO: 10)	KQSYNLLT (SEQ ID NO: 11)

[21] **BN/N/2022/0156** [22] **21/12/2022**

[54] **Il-10 Muteins And Fusion Proteins Thereof**

[71] **AMGEN INC of One Amgen Center Drive Thousand Oaks,, California 91320-1799, United States of America**

[72]

- 1. HSU, Hailing**
- 2. FOLTZ, Ian**
- 3. MOCK, Marissa**
- 4. LUNA, Victor Mitch**



5. ZHANG, Ming
6. WANNBERG, Sharon
7. CAMDERE TAPIA, Gamze Ozlem
8. RILEY, Timothy P.

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD** of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]

No. 63/045,041 Date: 26/06/2020 Country: United States of America

No. 63/199,218 Date: 14/12/2020 Country: United States of America

[86] **PCT/US2021/039191**

[87] **WO/2021/263167**

[51] **CO7K 14/5, A61K 38/20**

[57] **The present disclosure relates, in general, to muteins of IL-10 that are stable as monomers, antigen binding proteins that bind to TREM-1, and antigen binding proteins comprising IL-10 muteins and antigen binding moieties, e.g., anti-TREM-1 antibodies, and compositions thereof. The disclosure also provides methods of treating inflammatory disease, such as inflammatory bowel disease or ulcerative colitis, using the compositions.**

[21] **BN/N/2022/0157** [22] **27/12/2022**

[54] **A Hydraulic Screen Having A Joint With A Flow Path**

[71] **HALLIBURTON ENERGY SERVICES, INC. of 3000 N. SAM HOUSTON PKWY E., HOUSTON, TEXAS 77032-3219, United States of America**

[72]

1. MCCHESNEY, Ryan
2. MCLEARY, Gordon
3. GRANT, David

[74] **Messrs. HENRY GOH & CO SDN BHD** of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]


No. 16/945,689 Date: 31/07/2020 Country: United States of America

[86] **PCT/US2020/045793**

[87] WO/2022/025939

[51] E21B 43/08, E21B 43/10, E21B 34/14, E21B 33/126, E21B 43/12

[57] An apparatus for activating chambers of downhole hydraulic screens. The apparatus comprises an outer sleeve, an inner sleeve, and a flow path. The outer sleeve is coupled to one hydraulic screen on one end and another hydraulic screen on another end. The inner sleeve couples to base pipe at both ends. The flow path is an annulus defined between the outer diameter of the inner sleeve and the inner diameter of the outer sleeve. Hydraulic seals are formed at the interfaces between the inner sleeve and base pipe and the outer sleeve and hydraulic screens. In practice, the assembled apparatus and hydraulic screens are ran downhole to a production zone using production tubing and a running tool. Fluid from the surface is pumped into the production tubing, diverted therefrom, and into chambers of the hydraulic screens using the flow path to conduct fluid between the hydraulic screens.



[21] BN/N/2022/0158

[22] 28/12/2022

[54] Combination Of Zibotentan And Dapagliflozin For The Treatment Of Chronic Kidney Disease

[71] ASTRAZENECA AB of SE-151-85 Sodertalje, Sweden

[72] 1. GREASLEY, Peter
2. AHLSTRÖM, Christine
3. SKRTIC, Stanko
4. MENZIES, Robert
5. SUNNÅKER, Mikael
6. MERCIER, Anne-Kristina



[74] **Messrs. AIP Law of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]

No. 63/050,147 Date: 10/07/2020 Country: United States of America

No. 63/196,793 Date: 04/06/2021 Country: United States of America

[86] **PCT/IB2021/056177**

[87] **WO/2022/009163**

[51] **A61K 31/497, A61K 31/70, A61P 13/12**

[57] **The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.**

[21] **BN/N/2022/0159** [22] **28/12/2022**

[54] **Magnetic Coupler With Force Balancing**

[71] **Halliburton Energy Services, Inc of 3000 N. Sam Houston Parkway E. Houston, Texas 77032-3219, United States of America**

[72] **1. ORNELAZ, Richard, Decena
2. FRIPP, Michael, Linley**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[86] **PCT/US2016/068804**

[87] **WO/2018/125070**

[51] **H 02K 49/10**

[57] **A magnetic coupling system and a method of balancing a magnetic coupler are provided. The magnetic coupling system includes a follower magnet magnetically coupled to a drive magnet, and a magnetic balancing component located to a side of the follower magnet. Movement of the drive magnet induces corresponding movement of the follower magnet. The magnetic balancing component and the drive magnet exert attractive magnetic forces on the follower magnet in opposite directions.**




FIG. 1

[21] BN/N/2022/0160 [22] 29/12/2022

[54] **Rip1k Inhibitors**

[71] **RIGEL PHARMACEUTICALS, INC. of 1180 Veterans Boulevard, South San Francisco, California 94080, United States of America**

[72] **1. BHAMIDIPATI, Somasekhar
2. DARWISH, lhab
3. IRVING, Mark
4. KOLLURI, Rao
5. MASUDA, Esteban
6. SHAW, Simon
7. TAYLOR, Vanessa
8. YU, Jiaxin**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]
No. 63/047,194 Date: 01/07/2020 Country: United States of America

[86] PCT/US2021/039112


[87] WO/2022/005898

[51] **A61P 9/00, A61P 25/00, A61P 29/00, A61P 37/00, C07D 487/04, C07D 498/04, C07D 498/14, C07D 513/04, C07D 513/14, A61K 31/55, A61K 31/553, A61K 31/554**

[57] **Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP 1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The**



disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition. (I)





**REGISTRAR OF PATENT
BRUNEI DARUSSALAM**

PATENTS RULES [S 11/2013]

PATENT RENEWAL APPLICATION

Patent No.: BN/N/2019/0055
Date of Grant: 10 April, 2019
Term: 6th Year
Applicant(s) / Proprietor(s): SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.
Title of Invention: Method For Sealing Cavities In Or Adjacent To A Cured Cement Sheath Surrounding A Well Casing

Patent No.: BN/N/2019/0072
Date of Grant: 27 May, 2019
Term: 6th Year
Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC OIL AND GAS FRANCE
Title of Invention: Threaded Joint For Steel Pipes

Patent No.: BN/N/2021/0071
Date of Grant: 27 July, 2021
Term: 5th Year
Applicant(s) / Proprietor(s): GRABTAXI HOLDINGS PTE. LTD.
Title of Invention: Transportation Method And Apparatus

Patent No.: RE/R/2015/0051



Date of Grant:	19 November, 2014
Term:	9th Year
Applicant(s) / Proprietor(s):	WYETH LLC
Title of Invention:	Processes For The Convergent Synthesis Of Calicheamicin Derivatives

Patent No.:	RE/R/2016/0028
Date of Grant:	15 December, 2015
Term:	8th Year
Applicant(s) / Proprietor(s):	SUMITOMO METAL INDUSTRIES, LTD. VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention:	Threaded Joint For Pipes Having A Lubricating Coating

Patent No.:	RE/R/2016/0033
Date of Grant:	29 December, 2015
Term:	8th Year
Applicant(s) / Proprietor(s):	INCYTE HOLDINGS CORPORATION
Title of Invention:	Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile

Patent No.:	RE/R/2016/0044
Date of Grant:	19 November, 2015
Term:	8th Year
Applicant(s) / Proprietor(s):	ELI LILLY AND COMPANY
Title of Invention:	Anti-N3pglu Amyloid Beta Peptide Antibodies And Uses Thereof



Patent No.:	RE/R/2016/0046
Date of Grant:	25 November, 2015
Term:	8th Year
Applicant(s) / Proprietor(s):	ACCELERON PHARMA INC.
Title of Invention:	Actrii Receptor Polypeptides

Patent No.:	RE/R/2017/0061
Date of Grant:	28 December, 2016
Term:	7th Year
Applicant(s) / Proprietor(s):	VERTEX PHARMACEUTICALS INCORPORATED
Title of Invention:	Heterocyclic Modulators Of Atp-Binding Cassette Transporters

Patent No.:	RE/R/2018/0005
Date of Grant:	20 November, 2017
Term:	6th Year
Applicant(s) / Proprietor(s):	ASTEX THERAPEUTICS LIMITED
Title of Invention:	Pyrazolyl Quinoxaline Kinase Inhibitors

Patent No.:	RP/R/2007/0045
Date of Grant:	4 October, 2007
Term:	17th Year
Applicant(s) / Proprietor(s):	NOVARTIS AG
Title of Invention:	Substituted 3,5-Diphenyl -1,2,4-Triazoles And Their Use As



Pharmaceutical Metal Chelators

Patent No.: RP/R/2008/0023
Date of Grant: 20 February, 2008
Term: 18th Year
Applicant(s) / Proprietor(s): BAVARIAN NORDIC A/S
Title of Invention: Modified Vaccinia Ankara Virus Variant

Patent No.: RP/R/2008/0043
Date of Grant: 8 July, 2008
Term: 18th Year
Applicant(s) / Proprietor(s): JANSSEN PHARMACEUTICA N.V.
Title of Invention: Hiv Replication Inhibiting Pyrimidines

Patent No.: RP/R/2009/0015
Date of Grant: 30 April, 2009
Term: 16th Year
Applicant(s) / Proprietor(s): JANSSEN ALZHEIMER IMMUNOTHERAPY
Title of Invention: Prevention And Treatment Of Amyloidogenic Disease

Patent No.: RP/R/2011/0011
Date of Grant: 2 April, 2011
Term: 14th Year
Applicant(s) / Proprietor(s): PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AMERICA



Title of Invention: Coding Method, Decoding Method, Coding Apparatus, Decoding Apparatus, Program, And Integrated Circuit

Patent No.: RP/R/2011/0015

Date of Grant: 18 April, 2011

Term: 14th Year

Applicant(s) / Proprietor(s): PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AMERICA

Title of Invention: Coding Method, Decoding Method, Coding Apparatus, Decoding Apparatus, Program, And Integrated Circuit

Patent No.: BN/N/2020/0047

Date of Grant: 6 June, 2020

Term: 5th Year

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME LLC

Title of Invention: Compositions Comprising Streptococcus Pneumoniae Polysaccharide-Protein Conjugates And Methods Of Use Thereof

Patent No.: RE/R/2017/0042

Date of Grant: 15 February, 2017

Term: 7th Year

Applicant(s) / Proprietor(s): ENVIRORESOLUTIONS INC.

Title of Invention: Gas Scrubber Apparatus And Method

Patent No.: BN/N/2014/0114

Date of Grant: 8 December, 2014



Term: 10th Year
Applicant(s) / Proprietor(s): BERTHOLD SICHERT GMBH
Title of Invention: Underground Switch Cabinet For Electric Installation

Patent No.: BN/N/2015/0081
Date of Grant: 16 July, 2015
Term: 5th Year
Applicant(s) / Proprietor(s): SAIPEM S.A
VEOLIA EAU - COMPAGNIE GENERALE DES EAUX
VWS WESTGARTH LTD
TOTALENERGIES ONETECH
Title of Invention: Underwater Water Treatment Unit And Method For Cleaning Said Unit

Patent No.: BN/N/2015/0081
Date of Grant: 16 July, 2015
Term: 6th Year
Applicant(s) / Proprietor(s): SAIPEM S.A
VEOLIA EAU - COMPAGNIE GENERALE DES EAUX
VWS WESTGARTH LTD
TOTALENERGIES ONETECH
Title of Invention: Underwater Water Treatment Unit And Method For Cleaning Said Unit

Patent No.: BN/N/2015/0081
Date of Grant: 16 July, 2015
Term: 7th Year
Applicant(s) / Proprietor(s): SAIPEM S.A
VEOLIA EAU - COMPAGNIE GENERALE DES EAUX
VWS WESTGARTH LTD
TOTALENERGIES ONETECH



Title of Invention: Underwater Water Treatment Unit And Method For Cleaning Said Unit

Patent No.: BN/N/2015/0081

Date of Grant: 16 July, 2015

Term: 8th Year

Applicant(s) / Proprietor(s): SAIPEM S.A
VEOLIA EAU - COMPAGNIE GENERALE DES EAUX
VWS WESTGARTH LTD
TOTALENERGIES ONETECH

Title of Invention: Underwater Water Treatment Unit And Method For Cleaning Said Unit

Patent No.: BN/N/2015/0081

Date of Grant: 16 July, 2015

Term: 9th Year

Applicant(s) / Proprietor(s): SAIPEM S.A
VEOLIA EAU - COMPAGNIE GENERALE DES EAUX
VWS WESTGARTH LTD
TOTALENERGIES ONETECH

Title of Invention: Underwater Water Treatment Unit And Method For Cleaning Said Unit

Patent No.: BN/N/2015/0081

Date of Grant: 16 July, 2015

Term: 10th Year

Applicant(s) / Proprietor(s): SAIPEM S.A
VEOLIA EAU - COMPAGNIE GENERALE DES EAUX
VWS WESTGARTH LTD
TOTALENERGIES ONETECH

Title of Invention: Underwater Water Treatment Unit And Method For



Cleaning Said Unit

Patent No.:	BN/N/2016/0052
Date of Grant:	26 July, 2016
Term:	10th Year
Applicant(s) / Proprietor(s):	JAPAN PALLET RENTAL CORPORATION
Title of Invention:	Distribution Container Management System, Distribution Container Management Method, And Distribution Container Management Program

Patent No.:	BN/N/2018/0064
Date of Grant:	4 July, 2018
Term:	7th Year
Applicant(s) / Proprietor(s):	GRABTAXI HOLDINGS PTE LTD
Title of Invention:	System And Method For Driver Selection

Patent No.:	BN/N/2019/0138
Date of Grant:	10 December, 2019
Term:	5th Year
Applicant(s) / Proprietor(s):	ELI LILLY AND COMPANY ZYMEWORKS, INC.
Title of Invention:	Checkpoint Inhibitor Bispecific Antibodies

Patent No.:	RE/R/2013/0041
Date of Grant:	4 June, 2013
Term:	16th Year



Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: Mapk/Erk Kinase Inhibitors

Patent No.: RE/R/2015/0055

Date of Grant: 10 December, 2014

Term: 9th Year

Applicant(s) / Proprietor(s): PFIZER INC.

Title of Invention: Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives

Patent No.: RE/R/2016/0031

Date of Grant: 6 October, 2010

Term: 8th Year

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME LLC

Title of Invention: Iminothiadiazine Dioxide Compounds As Bace Inhibitors, Compositions, And Their Use

Patent No.: RE/R/2018/0008

Date of Grant: 15 December, 2017

Term: 6th Year

Applicant(s) / Proprietor(s): VALLOUREC MANNESMANN OIL & GAS FRANCE SUMITOMO METAL INDUSTRIES, LTD.

Title of Invention: Threaded Connection

Patent No.: BN/N/2014/0001

Date of Grant: 7 January, 2014

Term: 11th Year



Applicant(s) / Proprietor(s): CRYSTAL LAGOONS (CURACAO) B.V.

Title of Invention: Localised Disinfection System For Large Water Bodies

Patent No.: BN/N/2017/0109

Date of Grant: 19 December 2017

Term: 6th Year

Applicant(s) / Proprietor(s): SOLETANCHE FREYSSINET

Title of Invention: Fire Protection Device For A Structural Cable

Patent No.: RP/R/2008/0072

Date of Grant: 15 October, 2008

Term: 19th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: Dipeptidyl Peptidase Inhibitors

Patent No.: RP/R/2011/0045

Date of Grant: 1 November, 2011

Term: 17th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: Metastin Derivatives And Use Thereof

Patent No.: BN/N/2014/0046

Date of Grant: 26 July, 2014

Term: 11th Year



Applicant(s) / Proprietor(s): CCP TECHNOLOGY GMBH
Title of Invention: Process And System For Conversion Of Carbon Dioxide To Carbon Monoxide

Patent No.: BN/N/2014/0048
Date of Grant: 28 May, 2014
Term: 11th Year
Applicant(s) / Proprietor(s): CCP TECHNOLOGY GMBH
Title of Invention: Process And System For Generating Synthesis Gas

Patent No.: RE/R/2013/0023
Date of Grant: 25 February, 2013
Term: 17th Year
Applicant(s) / Proprietor(s): ARIAD PHARMACEUTICALS, INC.
Title of Invention: Bicyclic Heteroaryl Compounds

Patent No.: RP/R/2011/0052
Date of Grant: 29 December, 2011
Term: 15th Year
Applicant(s) / Proprietor(s): ELI LILLY AND COMPANY
Title of Invention: Morpholine Derivatives As Norepinephrine Reuptake Inhibitors

Patent No.: BN/N/2014/0062
Date of Grant: 7 July, 2014
Term: 11th Year



Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC MANNSMANN OIL & GAS FRANCE

Title of Invention: Threaded Joint For Pipes

Patent No.: BN/N/2016/0045

Date of Grant: 26 May, 2016

Term: 9th Year

Applicant(s) / Proprietor(s): CRYSTAL LAGOONS (CURACAO) B.V.

Title of Invention: Suctioning Device For Large Artificial Water Bodies

Patent No.: BN/N/2017/0063

Date of Grant: 12 January, 2016

Annuity: 8th Year

Applicant(s) / Proprietor(s): TMA CAPITAL AUSTRALIA PTY LTD

Title of Invention: System, Method And Computer Program For An Access Control System

Patent No.: BN/N/2019/0087

Date of Grant: 29 January, 2018

Annuity: 6th Year

Applicant(s) / Proprietor(s): ASTRAZENECA AB

Title of Invention: Estrogen Receptor Modulators

Patent No.: BN/N/2019/0088

Date of Grant: 16 January, 2018

Annuity: 6th Year



Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	Jak1 Selective Inhibitors
<hr/>	<hr/>
Patent No.:	RE/R/2015/0061
Date of Grant:	31 December, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	PURDUE PHARMA L.P.
Title of Invention:	Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising An Opioid Analgesic
<hr/>	<hr/>
Patent No.:	RE/R/2016/0016
Date of Grant:	8 January, 2016
Annuity:	8th Year
Applicant(s) / Proprietor(s):	JANSSEN SCIENCES IRELAND UC
Title of Invention:	Indoles As Respiratory Syncytial Virus Antiviral Agents
<hr/>	<hr/>
Patent No.:	RE/R/2017/0051
Date of Grant:	13 January, 2017
Annuity:	7th Year
Applicant(s) / Proprietor(s):	AGC INC SANTEN PHARMACEUTICAL CO., LTD.
Title of Invention:	Method And Composition For Treating Ocular Hypertension And Glaucoma
<hr/>	<hr/>
Patent No.:	RE/R/2018/0002
Date of Grant:	16 January, 2017
Annuity:	7th Year



Applicant(s) / Proprietor(s): CYTOKINETICS, INC.
Title of Invention: Certain Amino-Pyridazines, Compositions Thereof, And Methods Of Their Use

Patent No.: BN/N/2015/0043
Date of Grant: 5 February, 2015
Annuity: 9th Year
Applicant(s) / Proprietor(s): BIOGENIC CO. LTD.
NIPPON SUISAN KAISHA, LTD.
Title of Invention: Method For Producing Astaxanthin

Patent No.: BN/N/2016/0043
Date of Grant: 29 December, 2014
Annuity: 9th Year
Applicant(s) / Proprietor(s): CRYSTAL LAGOONS (CURACAO) B.V.
Title of Invention: System And Method For Maintaining Water Quality In Large Water Bodies

Patent No.: BN/N/2016/0070
Date of Grant: 3 March, 2015
Annuity: 9th Year
Applicant(s) / Proprietor(s): CHUA, BOON PEN
Title of Invention: A Method Of Priming A Drainage Apparatus For Siphoning Liquid, And A Drainage Apparatus

Patent No.: BN/N/2020/0041
Date of Grant: 19 November, 2018
Annuity: 5th Year
Applicant(s) / Proprietor(s): WEATHERFORD U.K. LIMITED



Title of Invention: Method And Apparatus For Washing An Annulus

Patent No.: RE/R/2012/0005

Date of Grant: 31 January, 2011

Annuity: 13^h Year

Applicant(s) / Proprietor(s): SUMITOMO METAL INDUSTRIES LTD.
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: Tubular Threaded Joint

Patent No.: RE/R/2014/0009

Date of Grant: 31 January, 2013

Annuity: 11th Year

Applicant(s) / Proprietor(s): ASTRAZENECA AB

Title of Invention: Chemical Compounds

Patent No.: RE/R/2018/0001

Date of Grant: 13 January, 2017

Annuity: 7th Year

Applicant(s) / Proprietor(s): CRYSTAL LAGOONS (CURACAO) B.V.

Title of Invention: Efficient Filtration Process Of Water In A Tank For Recreational And Ornamental Uses, Where The Filtration Is Performed Over A Small Volume Of Water And Not Over The Totality Of The Water From The Tank

Patent No.: RP/R/2010/0007

Date of Grant: 13 January, 2010

Annuity: 14th Year

Applicant(s) / Proprietor(s): SHELL INTERNATIONALE RESEARCH



MAATSCHAPPIJ B.V.

Title of Invention: **Method For Production Metering Of Oil Wells**



REGISTRAR OF PATENT

BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

PATENT GRANTED UNDER SECTION 30

Application No.: BN/N/2022/0029

Date of Grant: 3 January, 2023

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP.
THE WALTER AND ELIZA HALL INSTITUTE OF
MEDICAL RESEARCH
MSD R&D (CHINA) CO., LTD.

Title of Invention: Antimalarial Agents
